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Background: Crizotinib was granted accelerated approval by the Food and Drug Administration in 2011 for the
treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). To evaluate the efficacy
and safety of crizotinib, we performed a meta-analysis of published clinical trials using the random effect model.
Methods: The efficacy and safety of crizotinib was evaluated based on 1-year overall survival (OS), progression-free
survival (PFS), overall response rate (ORR), partial response, complete response, stable disease, and dose reduction
or cessation because of crizotinib toxicity.
Results: Six clinical trials were included in the meta-analysis. Crizotinib treatment demonstrated a 1-year OS of 66.8%
(95% CI, 52.2–78.8%) and a PFS of 8.6 months (95% CI, 7.3–9.9 months). The aggregate ORR, partial response and
complete response rates were 61.2%, 59.8% and 1.5%, respectively. The proportion of patients achieving stable disease
was 42.6% (95% CI, 17.3–72.5%). The most frequently reported adverse effects of crizotinib were mild visual disturbances,
nausea, vomiting, diarrhea, constipation, edema, reduction in glomerular filtration rate, and generally reversible
but sometimes severe elevations in aspartate aminotransferase and alanine aminotransferase. The proportion of
patients who required dose reduction or cessation because of crizotinib toxicity was 6.5% (95% CI, 4.1–10.1%).
Conclusions: This meta-analysis revealed extended survival and improved response rates in patients treated with
crizotinib. As a novel, targeted anticancer agent, crizotinib appears to be a favorable treatment option for patients
with locally advanced or metastatic ALK-positive NSCLC.
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Lung cancer, of which approximately 85–90% of cases
are non-small cell lung cancer (NSCLC), is the most
common fatal malignancy among all cancers worldwide,
and its incidence has gradually increased over recent de-
cades, [1,2]. Patients usually present with unresectable
locally advanced (stage IIIB) or distant metastases (stage
IV) NSCLC. For patients newly diagnosed with advanced
NSCLC, the median overall survival (OS) with platinum-* Correspondence: mafei2011@139.com
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unless otherwise stated.based chemotherapy is 7.4–9.9 months, and the median
OS with combined chemotherapy and bevacizumab is
12.5 months. Median progression-free survival (PFS)
with second-line chemotherapy, such as pemetrexed and
docetaxel, is approximately 2.2–2.9 months. Although
associated with a higher response rate, OS with gefitinib
is similar to that of standard carboplatin plus paclitaxel
chemotherapy [3]. The 5-year survival rate of NSCLC is
lower than 20% [4,5]. However, despite the relatively
poor prognosis for NSCLC patients, the development of
treatments for NSCLC has not yet kept pace [6].
In recent years, the identification of genetic abnormal-
ities that may underlie oncogenic development and pro-
gression have revolutionized oncology research [7]. Ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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kinase anaplastic lymphoma kinase (ALK), leading to the
expression of ALK fusion proteins, was first reported in
NSCLC patients in 2007 [8,9]. The activated ALK fusion
proteins result in aberrant ALK signaling and oncogenic
transformation through several molecular signaling path-
ways, including PI3K/AKT/mTOR, JAK/STAT, and RAS/
MEK/ERK [10]. Constitutive ALK signaling mediates en-
hanced cell proliferation, cell survival, and metabolism.
ALK gene rearrangements are found in approximately 2–
7% of unselected patients with NSCLC [11]. Because of
the role of ALK in oncogenesis, tyrosine kinase inhibition
has been investigated as a therapeutic approach [11]. Cri-
zotinib is a small-molecule selective inhibitor of ALK and
mesenchymal epithelial growth factor (c-Met)/hepatocyte
growth factor receptor (HGFR) kinases [12]. It was ap-
proved via accelerated drug approval by the US Food and
Drug Administration in 2011, based on the findings of
two early phase clinical trials demonstrating prolonged
progression-free survival (PFS; 6–10 months) and high re-
sponse rates (50–57%) in patients with ALK-positive
NSCLC [13,14]. A further phase 3 clinical trial in patients
with ALK-positive NSCLC confirmed the advantage of cri-
zotinib in survival, response rates, and duration of re-
sponse in ALK-positive patients with NSCLC, although
mild to severe adverse effects, commonly reported as
gastrointestinal disturbances (nausea, diarrhea, vomiting,
and constipation), visual disturbances and fatigue, were
noted [15,16].
This study systematically combines data from published
clinical trials to evaluate the efficacy and safety of crizotinib
in the treatment of ALK-positive NSCLC using a random
effect model following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [17].
Methods
Search strategy for the identification of studies
To evaluate the efficacy and safety of crizotinib in the treat-
ment of ALK-positive NSCLC, PubMed, Embase, and the
Cochrane Library (all from 1980 to Nov 2013) were
searched to identify clinical trials in English-language jour-
nals. The search terms used were “crizotinib”, “non-small
cell lung cancer”, “carcinoma”, “anaplastic lymphoma kin-
ase”, and “clinical trial” in various combinations. We also
manually searched the related references from the bibliog-
raphy of the selected articles. Only eligible original studies
with full text available were selected, and meeting abstracts
were excluded. The corresponding authors of some studies
were contacted for further information if necessary.
Article selection criteria
All clinical trials exploring the efficacy and safety of cri-
zotinib in the treatment of ALK-positive NSCLC wereconsidered eligible for the analysis. The inclusion criteria
were as follows: (i) articles were clinical trials investigat-
ing the efficacy and/or safety of crizotinib in the treat-
ment of ALK-positive NSCLC; (ii) a standardized effect
size could be calculated on the evaluations of 1-year
overall survival (OS), progression-free survival (PFS),
overall response rate (ORR), partial response, complete
response, stable disease, and/or dose reduction or cessa-
tion because of adverse effects of crizotinib were re-
ported; (iii) articles were in English; and (iv) full text was
available. Two investigators (MF and WH) independ-
ently assessed the articles for relevancy.
Data extraction
All articles were first de-identified (article title, author
names, journal name and year of publication) before se-
lection. The abstracts of the articles were independently
reviewed by two authors (MF and WH). Outcomes were
pooled for 1-year OS (defined as the percentage of pa-
tients who remained alive 1 year after crizotinib treat-
ment), ORR (defined as the observed alive rate of
patients since the date of crizotinib treatment), partial
response (defined as the percentage of patients who had
a decrease in the size of tumor, or in the extent of can-
cer in the body, in response to crizotinib treatment),
complete response (defined as the percentage of pa-
tients who had the disappearance of all signs of cancer
in response to crizotinib treatment), dose reduction or
cessation because of adverse effects of crizotinib, and
mean duration of PFS and stable disease. Data were fil-
tered and transferred into a standard electronic form.
Any discrepancies were resolved by discussion until a
consensus was reached. If not, the principal investigator
(QH) made the final decision on the eligibility of the
study and data extraction.
Statistical analysis
Data management and analysis were performed using
Comprehensive Meta-analysis Version 2 (Biostat, Englewood,
NJ, USA). Data were pooled statistically using the event
rates calculated for primary (the 1-year OS, ORR, partial
response, complete response) and secondary endpoints
(dose reduction or cessation because of crizotinib ad-
verse effects, and mean duration of PFS and stable
disease).
A random effect meta-analysis was conducted to investi-
gate the efficacy and safety of crizotinib in the treatment
of ALK-positive NSCLC in this study. Because fixed ef-
fects models in meta-analysis assume that one true effect
exists, which all studies are estimating, they increase the
risk of a Type I error and create overly narrow confidence
intervals. In contrast, random effects models assume that
true effects are different across studies owing to hetero-
geneity of patients, treatments or other factors. Random
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minimize the risk of Type I error. Therefore, random ef-
fects models are recommended to be routinely employed
in meta-analysis, particularly when study heterogeneity is
expected or found [18].
The measure of heterogeneity was evaluated using
Cochran’s Q-test. Additionally, heterogeneity was assessed
using the I2 statistic. A high value for I2 indicates het-
erogeneity. Publication bias was evaluated using Egger’s
test.
Ethical approval
The study was approved by the Ethics Committee of
the Cancer Hospital of Chinese Academy of Medical
Sciences.
Results
A total of 87 abstracts were initially selected through data-
base searching, and 63 articles were excluded because they
failed to meet the criteria. For the remaining 24 articles,Figure 1 Flow chart describing the article selection process.five had the same data presented in other studies, six did
not provide sufficient information to calculate an effect
size, and seven studies were case reports. The article
selection process is shown in Figure 1, and details of
the six articles [14,19-23] selected for our analysis are
shown in Table 1.
In these 6 studies, the efficacy and toxicity of crizo-
tinib was investigated in the treatment of ALK-positive
NSCLC. Analysis of pooled data revealed a 1-year OS of
66.8% (95% CI, 52.2–78.8%; Figure 2A) and a PFS of
8.6 months (95% CI, 7.3–9.9 months; Figure 2B). In
terms of response rates, the aggregate ORR (Figure 3A),
partial response (Figure 3B) and complete response
(Figure 3C) were 61.2% (95% CI, 57.4–64.8%), 59.8%
(95% CI, 56.0–63.5%) and 1.5% (95% CI, 0.8–2.8%), re-
spectively. The proportion of patients achieving stable
disease (Figure 3D) was 42.6% (95% CI, 17.3–72.5%).
The proportion of patients who required dose reduction
or cessation because of crizotinib toxicity was 6.5%
(95% CI, 4.1–10.1%, Figure 4).


















Shaw et al. [21] 50.0 173 12.2 250 mg twice daily Phase 3 95 95
Brosnan et al. [22] 54.7 38 16.3 250 mg twice daily NA NA NA
Riely [23] 53.0 261 12.0 250 mg twice daily Phase 2 92 NA
Camidge et al. [19] 52.0 149 16.3 250 mg twice daily Phase 1 97 NA
Shaw et al. [20] 51.0 56 18.0 250 mg twice daily Phase 1 96 89
Kwak et al. [14] 51.0 82 6.4 250 mg twice daily Phase 1 96 NA
NA = not applicable.
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OS (Q = 14.903, p = 0.002, I2 = 79.870) and stable disease
(Q = 122.520, p <0.001, I2 = 97.551). No significant differ-
ence was observed for other outcomes (p >0.05). Funnel
plots and Egger’s regression test revealed no significant
publication bias (p >0.05).
Discussion
The goal of this meta-analysis was to evaluate the efficacy
and safety of crizotinib in the treatment of ALK-positive
NSCLC. The aggregated effect size revealed that crizotinib
treatment shows generally extended survival (1-year OS:
66.8%; PFS: 8.6 months) and improved response rates
(ORR: 61.2%; partial response: 59.8%; complete response:
1.5%; stable disease: 42.6%). These findings strongly indi-
cate the effectiveness of crizotinib treatment in patients
with ALK-positive NSCLC. In a retrospective analysis of a
phase 1 trial [20], ALK-positive patients who received cri-
zotinib (n = 82) showed improved survival compared to
ALK-positive control patients (n = 36) who did not receive
crizotinib. In the second- and third-line settings, 1-year
OS was 70% versus 44%, respectively; and 2-year OS was
55% versus 12%, respectively. The effect of crizotinib treat-
ment (n = 173) was also compared with standard-of-careA B
Figure 2 Forest plot for the aggregate survival data of crizotinib in th
anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer
survival (PFS).NSCLC treatments (docetaxel or pemetrexed as a single
agent, n = 174) in ALK-positive patients with advanced
NSCLC previously treated with one platinum-containing
regimen in a Phase 3 trial [21]. Results showed that PFS
was prolonged in the crizotinib-treated group (7.7 months
vs. 3.3 months, p <0.0001). Patients in the crizotinib arm
completed more treatment cycles than those in the
standard chemotherapy arm. Response was significantly
improved (65% vs. 20%, p <0.0001). Thus, crizotinib
treatment demonstrated an improvement in survival
and response rates, which were superior to standard-of-
care chemotherapy. As a novel targeted anticancer
agent, crizotinib appears to be a favorable treatment
option for patients with locally advanced or metastatic
ALK-positive NSCLC.
Notably, 6.5% of patients have to reduce the dose or dis-
continue crizotinib treatment because of toxicity. In the
studies included in this meta-analysis, the most frequently
reported adverse effects were mild visual disturbances,
nausea, vomiting, diarrhea, constipation, edema, reduction
in glomerular filtration rate, and generally reversible but
sometimes severe elevations in aspartate aminotransferase
and alanine aminotransferase. Shaw et al. [21] found that
adverse events reported with crizotinib treatment of ALK-e treatment of patients with locally advanced or metastatic
(NSCLC). (A) 1-year overall survival (OS); (B) progression-free
A B
C D
Figure 3 Forest plot for the aggregate response data of crizotinib in the treatment of patients with locally advanced or metastatic
anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (A) overall response rate (ORR); (B) partial response;
(C) complete response; (D) stable disease.
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pemetrexed, with similar severe (grade 3 or 4) reactions
across the treatment groups. Discontinuation rates were
slightly higher in the chemotherapy arm (10%) compared
with the crizotinib arm (6%). Although generally tolerated,
the toxicity of crizotinib should be monitored in order to
maximize its safety [24,25], and the dose of crizotinib
needs to be adjusted when necessary [26].
As a newly approved medication, evidence of the effi-
cacy and safety of crizotinib in the treatment of ALK-
positive NSCLC is relatively incomplete. The findings
from this meta-analysis are therefore valuable for physi-
cians and public health policy makers in formulating strat-
egies to maximize the efficacy and minimize crizotinib
toxicity. However, given the relatively small numbers of
cases included into the trials, generalization of theFigure 4 Forest plot for the aggregate proportion of patients who r
toxicity in the treatment of locally advanced or metastatic anaplast
cancer (NSCLC).conclusions from this study to all patients with ALK-
positive NSCLC should be cautious.Conclusions
In conclusion, the meta-analysis investigated the efficacy
and safety of crizotinib in the treatment of patients with
locally advanced or metastatic ALK-positive NSCLC. Clin-
ical trials with crizotinib treatment show extended survival
and improved response rates, along with tolerable toxicity.
As a novel targeted anticancer agent, crizotinib appears to
be a favorable treatment option for patients with locally
advanced or metastatic ALK-positive NSCLC. Further
blinded, placebo-controlled studies with larger sample
sizes are needed to compare the efficacy and safety of
crizotinib with other NSCLC treatments.equired dose reduction or cessation because of crizotinib
ic lymphoma kinase (ALK)-positive non-small cell lung
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